CD80‑Targeted Antibody Tools: Deciphering Co‑Stimulation and Immune‑Checkpoint Crosstalk in Basic Immunology

Molecular Traits and Expression Patterns of CD80 (B7‑1) for Immune Research

CD80, also annotated as B7‑1, belongs to the immunoglobulin superfamily and represents a type‑I transmembrane glycoprotein with an approximate molecular weight of 60 kDa. Its structural architecture includes two extracellular immunoglobulin‑like domains, a transmembrane segment, and a short intracellular cytoplasmic tail.

CD80 expression stays low under resting physiological conditions and becomes strongly induced upon cellular activation within professional antigen‑presenting‑cell populations. Activated B‑cells, dendritic cells, macrophages and subsets of T‑cells can up‑regulate surface CD80 protein following appropriate stimulatory cues.

Compared with the related co‑signal molecule CD86 (B7‑2), CD80 exhibits delayed expression kinetics during the course of immune responses. This temporal pattern indicates that CD80 contributes more prominently to sustained immune modulation rather than early‑phase initiation events within experimental immune model systems.

Dual Signalling Outputs: CD80‑Mediated Co‑Stimulation versus Co‑Inhibition

CD80 engages two distinct surface receptors expressed by T‑lymphocyte populations to deliver opposing immunological signals. When CD80 binds to CD28 receptor complexes, it furnishes critical co‑stimulatory signals required for complete T‑cell activation downstream of TCR engagement.

This receptor‑ligand interaction supports naïve T‑cell proliferation, effector‑cell differentiation, and the production of key effector cytokines such as interleukin‑2 in cell‑based assay systems. In contrast, CD80 ligation to CTLA‑4 (CD152) transmits inhibitory intracellular signals to constrain excessive T‑cell activation.

Such negative signalling helps sustain immune homeostasis and lowers risks linked to auto‑reactive immune responses in vivo. A single CD80 molecule can thus shift immune outcomes by partnering with different receptors, marking it as a central regulatory hub within immune‑signal networks.

Cis‑Heterodimer Formation and Complex Crosstalk with the PD‑1/PD‑L1 Checkpoint Axis

Contemporary mechanistic studies uncover additional regulatory complexity originating from cis‑acting molecular interactions occurring within the same antigen‑presenting‑cell plasma membrane. CD80 can assemble into cis‑heterodimer complexes with PD‑L1 protein molecules on APC surfaces.

Once assembled, the PD‑L1 component within this cis‑complex loses capacity to engage PD‑1 receptors on neighbouring T‑cells, thereby reducing PD‑1‑driven immune suppression. Meanwhile, the CD80 subunit within the heterodimer retains functional competence to bind CD28 and deliver co‑stimulatory signals to T‑cell populations.

CTLA‑4‑expressing regulatory T‑cells execute trans‑endocytosis to selectively remove surface CD80 molecules from antigen‑presenting cells. This process disrupts pre‑existing PD‑L1‑CD80 cis‑heterodimers and releases free PD‑L1 protein, which restores PD‑1‑mediated inhibitory signalling circuits. These layered molecular events shape how experimental model systems respond to immune‑checkpoint‑targeted interventions.

Diverse Experimental Applications for CD80‑Specific Antibody Reagents

Validated anti‑CD80 antibody reagents serve multiple essential purposes across modern immunology laboratory workflows. Flow‑cytometry assays employ these antibodies to quantify activation status for myeloid populations such as M1‑polarized macrophages and dendritic‑cell subsets.

Immunohistochemistry and immunocytochemistry protocols utilise CD80 antibodies to map spatial protein‑expression patterns within preserved tissue sections. Blocking‑format anti‑CD80 antibodies can disrupt CD80‑CD28 molecular contacts to dissect contributions from co‑stimulatory signalling during T‑cell activation assays.

Within tumour‑microenvironment‑oriented research, CD80 detection antibodies enable researchers to assess the functional activation state of tumour‑infiltrating antigen‑presenting‑cell populations. All these experimental workflows demand antibody reagents with well‑documented target specificity and consistent batch‑to‑batch performance metrics.

Anti‑CD80 Antibody Portfolio from ANT BIO PTE. LTD. for Immunology Mechanism Studies

ANT BIO PTE. LTD. supplies a panel of recombinant anti‑CD80 antibody clones for human and mouse‑oriented basic‑research projects. Clone S‑288‑154 and clone S‑288‑177 are recombinant rabbit monoclonal antibodies targeting human CD80 protein and have completed target‑validation and batch‑consistency quality‑control procedures.

Additional rat‑derived recombinant anti‑mouse CD80 reagent supports in‑vivo experimental setups. Validated application platforms cover Western blot, immunohistochemistry, and immunocytochemistry workflows. These reagents support mechanistic exploration of T‑cell co‑stimulation, immune‑checkpoint crosstalk, and tumour‑immune‑microenvironment profiling tasks.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.